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Abstract
Background: Development of autoimmune diseases is the result of a complex interplay between hereditary and
environmental factors, with multiple genes contributing to the pathogenesis in human disease and in experimental
models for disease. The T-box protein 3 is a transcriptional repressor essential during early embryonic development,
in the formation of bone and additional organ systems, and in tumorigenesis.
Methods: With the aim to find novel genes important for autoimmune inflammation, we have performed genetic
studies of collagen-induced arthritis (CIA), a mouse experimental model for rheumatoid arthritis.
Results: We showed that a small genetic fragment on mouse chromosome 5, including Tbx3 and three additional
protein-coding genes, is linked to severe arthritis and high titers of anti-collagen antibodies. Gene expression
studies have revealed differential expression of Tbx3 in B cells, where low expression was accompanied by a
higher B cell response upon B cell receptor stimulation in vitro. Furthermore, we showed that serum TBX3
levels rise concomitantly with increasing severity of CIA.
Conclusions: From these results, we suggest that TBX3 is a novel factor important for the regulation of gene
transcription in the immune system and that genetic polymorphisms, resulting in lower expression of Tbx3,
are contributing to a more severe form of CIA and high titers of autoantibodies. We also propose TBX3 as a
putative diagnostic biomarker for rheumatoid arthritis.
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Background
Rheumatoid arthritis (RA), affecting 0.5–1% of the world’s
population, is characterized by chronic inflammation,
which primarily affects the synovial joints leading to tissue
damage and physical disability. Furthermore, the conse-
quences of immunological abnormalities and systemic in-
flammation may lead to premature mortality. The disease
follows a heterogeneous clinical course with a gender bias
towards women. The etiology mainly remains unknown
due to the multifactorial nature and complexity of the dis-
ease. Both genetic and environmental factors are reported
to play a role in the predisposition to RA [1]. Genes within
the major histocompatibility complex (MHC), also called
the human leukocyte antigen (HLA) complex, are the
strongest genetic factors for RA [2]. In addition, a large
number of non-MHC genes have been shown to contrib-
ute to RA pathogenesis [3, 4].
Despite the introduction of new, effective therapies for
RA, not all patients respond to the available treatments.
Therefore, there is an unmet need for novel drugs and
better biomarkers that can improve early detection, de-
termine prognosis and disease activity, stratify patients
for various therapeutic options, and monitor the re-
sponse to therapy [5]. Novel biomarkers should be ro-
bust in their association with disease activity and offer
predictive value in selection of appropriate therapy.
Experimental animal models, providing a genetically
homogeneous and well-controlled experimental environ-
ment, are invaluable tools in genetic studies and drug and
biomarker discovery in RA, whereby collagen-induced
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arthritis (CIA) is the most commonly used model [6].
After immunization with bovine collagen type II (CII),
the B10.RIII mouse strain develops CIA, whereas the
MHC-matched RIIIS/J mouse strain is resistant to arth-
ritis development. The two particular mouse strains are
therefore suitable for studies of non-MHC genes in-
volved in the development of CIA [7, 8]. A strategy in-
volving gene-segregating crosses between the two mouse
strains, and development of congenic mice, allows for
identification of novel non-MHC candidate genes and re-
lated disease pathways [9].
The genetic locus Eae39, located on mouse chromo-
some 5, was previously linked to experimental auto-
immune encephalomyelitis (EAE), an experimental model
for multiple sclerosis. Subsequently, it was also shown to
influence CIA development and severity [8, 10]. Eae39
congenic and sub-congenic lines were bred on the genetic
background of the B10.RIII strain [7]. In the present study,
the Eae39 sub-locus, Eae39r, was investigated. This locus
comprises four protein-coding genes: Mediator complex
subunit 13-like (Med13l), T-box transcription factor 3
(Tbx3), T-box transcription factor 5 (Tbx5), and Probable
RNA-binding protein 19 (Rbm19). The MED13L protein
is part of the cyclin-dependent kinase (CDK)-8 module of
the mediator complex and acts as a key regulator of RNA
polymerase II-dependent gene transcription [11, 12]. The
Rbm19 gene encodes for a protein contributing to riboso-
mal (r) RNA processing, a key step in ribosome biogenesis
[13]. It belongs to a group of RNA binding proteins (RBPs)
that have been associated with neurological disorders,
cancers and inflammatory diseases [14]. However, the
exact function and role of Rbm19 in disease associa-
tions have not been well-studied.
The T-box genes Tbx3 and Tbx5 are closely linked and
share 98% and 96% homology between mouse and hu-
man, respectively [15]. TBX5 acts as a transcription acti-
vator [16], whereas TBX3 functions predominantly as a
transcriptional repressor. Nevertheless, TBX3 contains
both activation and repression domains that are sug-
gested to be modulated in different cellular milieus [17,
18]. Among other functions, both proteins are involved
in bone development [18–20] and remodeling [21].
Mutations in the human TBX3 and TBX5 genes cause
ulnar-mammary syndrome (UMS, OMIM 181450) and
Holt-Oram syndrome (HOS, OMIM 142900), respect-
ively. Both syndromes cause defects in limb development
[16, 22], which asserts their link to bone pathways recently
recognized to interact with immune pathways [23]. How-
ever, the role of the TBX3 and TBX5 proteins in the im-
mune system, their link to RA, and their biomarker
potential, remains unexplored.
With the aim to elucidate the role of the Eae39r gen-
etic locus in autoimmune inflammation, we investigated
CIA pathogenesis in B10.RIIIS/J-Eae39r congenic and
sub-congenic mice, followed by studies of polymor-
phisms, gene transcription, and protein expression. We
report that mice with allelic variants in the upstream
and downstream regions of the Tbx3, Tbx5, and Rbm19
genes, develop more severe CIA compared to littermate
controls. In addition, these mice develop significantly
enhanced anti-CII antibody responses and have altered
B cell response upon activation in vitro. In the present
study, we identified reduced expression of Tbx3 in the
spleens of sub-congenic mice and showed that activa-
tion of B cells is concomitant with a changed level of
active TBX3 protein. This study gives novel insight into
CIA candidate genes and provides the first evidence for
TBX3 as an RA candidate gene and putative RA bio-
marker, thereby furthering our understanding of the
disease pathogenesis.
Methods
Mice
BR.RIIIS/J-Eae39r congenic mice were produced by
introduction of the Eae39r fragment from the CIA-re-
sistant RIIIS/J donor strain, purchased from Jackson
Laboratory (Bar Harbor, ME, USA), to the CIA suscep-
tible B10.RIII background strain, provided by J. Klein
(Tübingen, Germany), as previously described [8]. The
sub-congenic line BR.RIIIS/J-Eae39r2 was produced by
further inter-crossing heterozygous BR.RIIIS/J-Eae39r
mice. All mice were kept and bred under standard con-
ditions in the animal facility at the Department of Drug
Design and Pharmacology, Faculty of Health and Med-
ical Sciences, University of Copenhagen, Denmark. The
Danish Animal Experiment Inspectorate license num-
ber is 2010/561–1920 and 2015-15-0201-00794.
Genotyping
Genomic DNA (gDNA) was purified from mouse ear
biopsies with High Pure PCR template preparation kit
(11796828001; Roche Holding AG, Basel, Switzerland)
according to the manufacturer’s protocol. Purified gDNA
was used for genotyping by high-resolution melting
(HRM) SNP genotyping for rs33583463 (5:118596773
bp; mouse genome assembly GRCm38) and rs29824716
(5:120043597 bp; mouse genome assembly GRCm38),
and by PCR-agarose gel electrophoresis method for the
homemade microsatellite marker D5tbxhm17 (5:119660
373 bp; mouse genome assembly GRCm38). HRM analysis
was carried out on the Roche LightCycler 480 using High
Resolution Melting Master (04909631001, Roche Holding
AG, Basel, Switzerland) as described elsewhere [26].
Microsatellite marker genotyping was determined by
analyzing PCR products on a MegaBACE1000 genotyping
system (Amersham Biosciences, Little Chalfont, UK) or
on a 3% agarose gel as previously described [9]. Primer
sequences are provided in the Additional file 1: Table
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S1. Based on genotype, mice were allocated into homo-
zygous congenic, sub-congenic or wild type control
groups for various experiments.
Induction and evaluation of CIA
CIA was induced in 8–10 weeks old male mice by intra-
dermal injection of 100 μg bovine CII (CII-7806; Sigma-
Aldrich, St Louis, MO, USA) emulsified in incomplete
Freund’s adjuvant (IFA) (F5506; Sigma-Aldrich, St Louis,
MO, USA) at the base of the tail (day 0) followed by a
booster dose of 50 μg CII emulsified in IFA on day 35.
Clinical disease was monitored in a blinded manner
three times a week, whereby arthritis was evaluated based
on inflammation (erythema and swelling) of affected
joints. Each mouse received a score according to a scor-
ing system whereby each inflamed toe (first phalanx ex-
cluded), all inflamed knuckles and inflamed wrist or
ankle were assigned one point giving a maximum of 6
points per paw and a theoretical maximum score of 24
per mouse. According to the Danish Animal Experi-
ment Inspectorate approved humane endpoints, mice
receiving scores above 10 were euthanized. The experi-
ment was terminated when no mice (irrespective of
group) developed arthritis in previously non-affected paws
on three consecutive observations or when the groups
were left too small for adequate statistical power.
For comparison of CIA development between con-
genic, sub-congenic and control groups, arthritis scores
for mice belonging to a particular genotype were analyzed
together in order to calculate mean score versus days after
immunization (disease progression), mean maximum
score (disease severity), incidence, ethical survival, mean
day of onset, and area under the curve (AUC; the sum of
scores during the course of the disease).
A total of 24 male B10.RIII mice were used for the
time-course CIA study, whereby 20 mice were immu-
nized and 4 were left unimmunized. CIA was induced
on day 0, by subcutaneous immunization with 100 μg
CII emulsified in IFA containing 50 μg Mycobacterium
tuberculosis H37Ra (DIFCO laboratories, Detroit, MI,
USA) and boosted on day 35 with 50 μg CII in IFA.
CIA was scored as aforementioned and four mice were
sacrificed on different days of the experiment, covering
pre-clinical (day 7, 15, and 25), onset/progressive (day
42) and late (day 68) phases of CIA. Blood was col-
lected for serum analysis, paws were snap-frozen in li-
quid nitrogen for later analysis and spleen was used for
isolating CD19+ B cells for DNA activity assay.
Enzyme-linked immunosorbent assay (ELISA)
For anti-CII ELISA, serum was prepared from blood
collected on days 0 and 15 (by submandibular bleed-
ing), and on the last day of CIA (by cardiac puncture).
The levels of CII-specific IgM, IgG1, IgG2c, and IgG3
antibodies were determined as previously described [8].
Briefly, serum dilutions were applied to 96-well micro-
titer plates (Nunc maxisorp, Roskilde, Denmark) coated
overnight with CII in PBS (0.5 μg/well) and subse-
quently blocked with 1% BSA/PBS solution. The
antigen-antibody binding signal was revealed by bio-
tinylated secondary antibodies: goat anti-mouse IgM
(1020–08), anti-IgG1 (1070–08), anti-IgG2c (1079–08),
and anti-IgG3 (1100–08) (SouthernBiotech, Birmingham,
AL, USA) and Avidin-HRP (554058, BD Pharmingen, San
Jose, CA, USA), followed by detection with 2,2′-Azinobis
[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt
(ABTS) substrate (A1888; Sigma-Aldrich, St Louis, MO,
USA). A SpectraMax Microplate Reader (Molecular De-
vices Corporation, Sunnyvale, CA, USA) was used to read
the absorbance at a wavelength of 405 nm with a wave-
length correction set to 492 nm. Pooled serum from arth-
ritic mice were used as a standard and the antibody levels
were measured as arbitrary concentrations.
For interleukin-2 (IL-2) cytokine ELISA, supernatants
from triplicate CD4+ T lymphocyte cultures were col-
lected at 48 h and analyzed by standard protocol for
sandwich ELISA described elsewhere (BD Biosciences,
Immune function analysis application handbook).
Sequencing and bioinformatics analysis
The borders of the congenic and sub-congenic frag-
ments were mapped using the aforementioned genotyp-
ing markers, spanning the Eae39r fragment, and were
fine-mapped by sequencing the genetic regions around
those borders by Sanger sequencing (GATC biotech,
Germany). The genomic locations of the borders and of
single nucleotide polymorphisms (SNPs) used for fine-
mapping are shown in Fig. 1. Using the defined borders,
genetic elements located in the congenic and sub-congenic
fragments, their biotype [27] and expression details [28]
were determined, followed by literature mining. PubMed
[29] and Google Scholar [30] databases were searched
using the keywords collagen-induced arthritis, rheuma-
toid arthritis, autoimmunity, inflammation, lympho-
cytes, and cell signaling. The retrieved information was
used to prioritize the genes for further studies.
To identify genetic variations in protein coding genes
located in the Eae39r2 sub-congenic fragment, Sanger
sequencing (GATC biotech, Germany), followed by
computational analysis, was performed. All coding
exons and regulatory regions of the Tbx3 and Tbx5
genes, including promoters (2 kb upstream of transcrip-
tional start site), 5’ UTR, and 3’ UTR, in addition to re-
gions containing documented non-synonymous SNPs
for the Rbm19 gene were sequenced (primers are listed
in Additional file 1: Table S2). The genomic locations
of these regions, based on mouse genome build GRC
m38, were retrieved from Ensembl [27].
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The identified variants were classed based on their re-
lationship to genes in the dbSNP [31] and Ensembl [27]
databases. Furthermore, web-based prediction tools were
used to check for possible effect of intronic and 5’/
3’UTR variants on transcription factor binding [32, 33]
and micro RNA (miRNA) binding [34], respectively. For
prediction of transcription factor binding site (TFBS) 20
nt region around the confirmed SNPs, between B10.RIII
and B10.RIIIS/J-Eae39r2 mice, was checked for differ-
ence in binding using two prediction tools, CONSITE
[32] and PROMO [33]. The disruption/introduction of
TFBS was reported with respect to background strain
i.e. B10.RIII.
Isolation of B and T lymphocytes
Mouse spleens were harvested and mashed through a
40-μm cell strainer to prepare single-cell suspensions
followed by depletion of red blood cells using BD Lys-
ing Buffer (555899; BD Biosciences, San Jose, CA,
USA). CD19+ B lymphocytes for cell proliferation assay,
real time PCR, and TBX3 activity assay, were positively
selected from splenic cell suspensions by using the
Fig. 1 Markers defining the location of the Eae39r locus, and the Eae39r1 and Eae39r2 sub-loci on mouse chromosome 5, and the genetic elements
included in the Eae39r region. SNP Ids in bold (black) represent the borders of the congenic and sub-congenic fragments. The SNP Ids/microsatellite
markers shown in gray were used for genotyping. Solid gray represents RIIIS/J alleles bred on to the B10.RIII background (white), while the diagonally
lined gray represents regions of unknown genotype. The genetic elements defining the Eae39r fragment are shown in tabular form along with their
location and biotype (according to Ensembl release 74) and protein coding genes are bolded. Mbp, mega base pair; SNP, single nucleotide
polymorphism; lincRNA, long intervening noncoding RNA; rRNA, ribosomal RNA. (+) = forward strand, (−) = reverse strand
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EasySep™ CD19 selection kit (18954; Stemcell Technolo-
gies, Vancouver, Canada) according to the manufacturer’s
recommended protocol. Pan T lymphocytes for real time
PCR and CD4+ T lymphocytes for cell proliferation
assay were isolated from the CD19− flow-through using
EasySep™ T cell isolation kit (19851; Stemcell Technolo-
gies, Vancouver, Canada) and EasySep™ CD4+ T cell en-
richment kit (19752; Stemcell Technologies, Vancouver,
Canada), respectively. Cell purity was > 90% for CD19+
B cells and > 92% for pan T and CD4+ T cells, as deter-
mined by flow cytometry.
Cell cultures, stimulation, and proliferation assay
Purified B lymphocytes were plated at 3 × 105 per
well in round-bottomed 96-well cell culture plates
(Corning, New York, USA). The cells were cultured
in complete Dulbecco’s modified eagle’s medium (DMEM)
GlutaMAX-I (61965026), 5% heat-inactivated fetal bovine
serum (FBS- 10082139), 1 mM HEPES (15630056), 50 μM
2-Mercaptoethanol (31350010), and 1% penicillin/strepto-
mycin (10378016; Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA), alone or in the presence of 0–
10 μg/ml lipopolysaccharide (LPS) (L2880; Sigma-Aldrich,
St Louis, MO, USA), 0–40 μg/ml goat anti-mouse IgM F
(ab’)2 (115–006-075; Jackson ImmunoResearch Laborator-
ies, Inc. Baltimore, PA, USA) or a combination of 0–
4 μg/ml anti-mouse CD40 antibody, clone 1C10 (14–
0401; eBioscience, San Diego, CA, USA) and 10 ng/ml
mouse IL-4 recombinant protein (14–8041; eBioscience,
San Diego, CA, USA). For CD4+ T cells, 105 purified
cells per well were stimulated with plate-bound purified
anti-mouse CD3 antibody, 0-3 μg/ml, clone 145-2C11
(550275; BD Biosciences, San Jose, CA, USA) and anti-
mouse CD28 antibody, fixed at 3 μg/ml, clone 37.51
(16–0281; eBioscience, San Diego, CA, USA). After cul-
turing for 48 h at 37 °C in 5% CO2, the cells were
pulsed for 16–18 h with 1 μCi per well 3H-thymidine
(Perkin Elmer, Waltham, MA, USA), and incorporation
was measured on a TopCount Scintillation Counter
(Perkin Elmer, Waltham, MA, USA) as counts per mi-
nute (cpm).
For the time-course CIA, purified B cells from CII im-
munized mice, at the indicated time points, were cul-
tured for 48 h in complete DMEM 5% FCS at 37 °C, 5%
CO2 with or without stimulation with a fixed concentra-
tion of anti-mouse IgM F (ab’)2 (10 μg/ml).
Flow cytometric analysis
Single-cell suspensions of spleen tissue were prepared in
complete DMEM as described above: 1 × 106 cells were
pre-incubated with 1 μg of Fc receptor block (anti-
CD16/CD32 antibody clone 93; 14–0161-81, eBioscience,
San Diego, CA), prior to staining with 0.1 μg of antibodies
for 15 min on ice. Rat anti-mouse CD19 fluorescein
isothiocyanate (anti CD19-FITC) antibody clone 1D3
(553785), anti-mouse CD4-phycoerytherin (anti CD4-PE)
antibody clone GK1.5 (553730), and anti-mouse CD8-
phycoerytherin-cyanine 5 (anti CD8-PE-Cy5) antibody
clone RPA-T8 (555368), all purchased from BD Biosci-
ences (San Jose, CA, USA) were used. The stained cells
were analyzed using Gallios Flow Cytometer (Beckman
Coulter, Brea, CA, USA) and FlowJo software (Tree
Star Inc., Ashland, OR, USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
For transcript quantification, snap-frozen whole ankle
joints (including synovium, adjacent tissues, and bones)
were pulverized using a mortar and pestle, followed by
homogenization with IKAT-10 Ultra-Turrax homogenizer
(IKA-Works, Staufen im Breisgau, Germany). Snap-frozen
spleen tissue was also homogenized with IKA T-10 Ultra-
Turrax homogenizer. Total RNA was extracted from joint
and spleen homogenates using the RNeasy Plus Universal
Mini Kit (73404; Qiagen, Hilden, Germany) and from
purified splenic B and T lymphocytes using the RNeasy
Micro Kit (74034; Qiagen, Hilden, Germany) followed
by removal of gDNA remnants by Turbo DNA free kit
(AM1907; Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol. The concentration and
purity of total RNA was measured on the NanoDrop
2000 (Thermo Fisher Scientific, Waltham, MA, USA),
while integrity was verified on a 1% agarose gel. Com-
plementary DNA (cDNA) was synthesized from 1 μg of
extracted RNA using Superscript III First Strand Syn-
thesis Kit (11752–250; Invitrogen, Carlsbad, CA, USA)
and SYBR green-based real time PCR was performed
with PrecisionPlus qPCR Mastermix (Primerdesign Ltd.,
Eastleigh, UK) and LightCycler480 Real-Time PCR System
(Roche, Mannheim, Germany). Relative quantification
was performed by calculating 2^(−delta delta CT)
(2-ΔΔCT), whereby ΔΔCT was taken as the difference
in normalized crossing threshold (CT) values between
experimental (sub-congenic) and control samples, and
the CT values of both groups were normalized to Ubiqui-
tin C (Ubc) as a housekeeping gene. Primer sequences are
listed in Additional file 1: Table S3.
DNA binding activity assay for TBX3
TBX3 activity was measured in the nuclear lysate of un-
stimulated and B cell receptor (BCR)-stimulated CD19+
B cells, and joint tissue homogenates using pre-validated
TFact™ DNA binding ELISA kit (TFE-7159; Assay Bio-
technology, Sunnyvale, CA, USA). The nuclear extraction
was performed with few changes while the immunoassay
was done according to the manufacturer’s protocol.
Briefly, the cells were lysed on ice for 15 min in a
hypo-osmotic lysis buffer (10 mM HEPES, 10 mM KCl,
1.5 mM MgCl2, and 0.1 mM DTT) containing protease
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and phosphatase inhibitors-PPI (05892791001; Roche
Diagnostics GmbH, Mannheim, Germany). The nu-
clear proteins were then extracted in the provided nu-
clear extraction buffer with PPI by incubating the
samples on ice for 40 min and vortexing intermittently.
A Pierce BCA Protein Assay (23227; Thermo Fisher
Scientific, Waltham, MA, USA) was employed to de-
termine the amount of nuclear proteins in all samples
using known concentrations of BSA as standards.
The extracted nuclear samples were applied to the
wells pre-coated with oligonucleotides specific for bind-
ing TBX3 and incubated overnight at 4 °C. Following
incubation with TBX3 primary antibody (for 2 h), and
HRP-conjugated secondary antibody (for 1 h), 3, 3′, 5,
5’-tetramethylbenzidine (TMB) substrate was added to
allow color development, which was quenched after 20
min by addition of stop solution. Absorbance of each
well was determined at a wavelength of 450 nm (correc-
tion set to 540 nm) using a SpectraMax Microplate
Reader (Molecular Devices Corporation, Sunnyvale,
CA, USA). Active TBX3 levels were measured as a rela-
tive concentration in comparison to standard curve of
nuclear lysate positive control (NLPC) provided in the
assay kit.
Serum quantification of TBX3
TBX3 was quantitated in serum samples, from the time-
course CIA study, using a pre-validated mouse TBX3
ELISA Kit (MBS2886293; MyBioSource, Inc. San Diego,
CA, USA). Standard sandwich ELISA was performed ac-
cording to the manufacturer’s protocol with few changes
in incubation time and temperature to reduce the back-
ground signal. Briefly, 100 μl of appropriate dilutions of
TBX3 standard (0–2.5 ng/ml) and samples were applied
per well to the 96-well microtiter plate pre-coated
with TBX3 capture antibody. The plate was incubated
overnight at 4 °C followed by addition of the recom-
mended amount of biotin-conjugated detection anti-
body (detection reagent A). After 2 h incubation at
room temperature and washing steps, avidin-HRP (de-
tection reagent B) was added at room temperature for
1 h. TMB substrate was added to allow color develop-
ment, which was quenched after 20 min by addition of
0.1 M H2SO4 stop solution. Absorbance of each well
was determined at a wavelength of 450 nm (correction
set to 540 nm) using a SpectraMax spectrophotometer.
The sensitivity limit of the assay was 0.091 ng/ml, and
the inter-assay and intra-assay coefficient of variation
(CV) was ≤ 10%, as reported by the manufacturer.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 7.03. All data on CIA (except disease incidence
and ethical survival data), ELISA, in vitro proliferation,
and TBX3 activity were analyzed using the Mann-Whit-
ney U test. The chi-square test and Fischer’s exact test
were applied for analysis of CIA incidence and ethical
survival data, respectively. RT-PCR data were analyzed
by two-way Student’s t test. P-values less than 0.05 were
considered significant in all cases.
Results
The Eae39r2 locus controls arthritis development and
anti-CII antibody response
In order to further dissect the genetics of the previously
reported non-MHC locus Eae39r [8, 35] and its impact
on CIA in mice, we established an B10.RIIIS/J-Eae39r
congenic mouse line, carrying the Eae39r fragment from
the CIA-resistant RIIIS/J (H-2r) strain on the background
genome of the CIA-susceptible B10.RIII (H-2r) strain,
and two Eae39r sub-congenic mouse lines: B10.RIIIS/
J-Eae39r1 and B10.RIIIS/J-Eae39r2 (Fig. 1). Arthritis
development was studied in the B10.RIIIS/J-Eae39r
congenic and B10.RIIIS/J-Eae39r2 sub-congenic mice by
immunization with bovine CII and the results from the
clinical arthritis scoring showed that B10.RIIIS/J-Eae39r
congenic and B10.RIIIS/J-Eae39r2 sub-congenic mice de-
veloped significantly more severe arthritis compared to
their littermate control mice (Fig. 2a-d and Table 1). These
results show that the Eae39r2 locus harbors genes that
control the development of CIA. Similar results were ob-
tained in a second independent CIA study comparing the
B10.RIIIS/J-Eae39r2 sub-congenic and control mice (data
not shown).
The disease-enhancing effect from the Eae39r2 genetic
fragment was also accompanied by significantly higher
titers of anti-CII antibodies, compared with littermate
controls, in both early (day 15) and late (day 72) phases
of disease (Table 2). This shows that genes in this region,
in addition, control antibody responses to CII, which
constitute a major part of the CIA pathogenesis [36].
Tbx3 and Tbx5 are candidate genes in the Eae39r2 locus
Sanger sequencing of documented SNPs from mouse
genome databases, in and around the Eae39r locus,
allowed the determination of borders of the congenic
and sub-congenic fragments as closely as possible,
thereby narrowing down the list of genes that could be
responsible for the CIA-enhancing effect. The Eae39r
fragment spanned over 1.8 Mbp, between rs33731225
(5:118442102 bp) and rs32160309 (5:120248221 bp);
and Eae39r2 was defined to be 1.4 Mbp, between rs5
1153450 (5:118811970 bp) and rs32160309 (5:12024
8221 bp) (Fig. 1). Since Eae39r2 was the smallest frag-
ment controlling CIA development, further focus of
this study was restricted to this fragment. Using online
resources, all protein-coding and non-protein-coding
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genetic elements located within the Eae39r2 locus were
listed (Table 3).
Among all, Tbx3 and Tbx5 were chosen as potential
candidate genes based on their conservation between
mouse and human, documented role in transforming
growth factor-beta (TGF-β) [37], bone morphogenic
protein (BMP) [38, 39], Hedgehog (Hh) [18], and
Wnt/β-catenin [40, 41] bone signaling pathways, the
link of mutations in these genes to human disorders
involving bone phenotype [16, 22], and reported ex-
pression in spleen and bone of the C57BL6 mouse
strain [28].
Fig. 2 Collagen-induced arthritis (CIA) development in B10.RIIIS/J-Eae39r and B10.RIIIS/J-Eae39r2 congenic and sub-congenic mice in comparison
to littermate controls. a CIA progression in B10.RIIIS/J-Eae39r congenic mice represented as mean arthritis score for each group ± standard error
of the mean (SEM). b Ethical survival curve for B10.RIIIS/J-Eae39r congenic mice - based on the animal healthcare inspectorate guidelines that
mice attaining a total score > 10 should be euthanized. c CIA progression and d ethical survival in B10.RIIIS/J-Eae39r2 sub-congenic mice. Data
were analyzed using the Mann-Whitney U test for disease progression and the chi-squared test for ethical survival; *p < 0.05, **p < 0.01
Table 1 Collagen-induced arthritis (CIA) phenotypes in Eae39r congenic and Eae39r2 sub-congenic mice
Disease parameter
(phenotype)
Experimental group
Eae39r congenic
(n = 11)
Littermate controls
(n = 15)
p valuea Eae39r2 sub-congenic
(n = 10)
Littermate controls
(n = 19)
p valuea
Incidence 9/11 (82%) 8/15 (53%) 0.2167 10/10 (100%) 15/19 (79%) 0.2680
Mean max scoreb 9.7 ± 1.6 3.9 ± 1.3 0.0041** 8.30 ± 1.14 4.4 ± 0.8 0.0118*
AUCc 80.8 ± 18 29.7 ± 11.2 0.0120* 67.8 ± 17.6 25.7 ± 7.2 0.0134*
Mean day of disease onset 42.2 ± 2.6 36.3 ± 3.4 0.1942 47.9 ± 3.4 53.6 ± 2.9 0.2529
Number of mice euthanizedd 7/11 (64%) 3/15 (20%) 0.0426* 5/10 (50%) 2/19 (10.5%) 0.0302*
aData on the incidence and number of mice euthanized were analyzed using the chi-squared test and the other variables were analyzed using the Mann-Whitney
U test; *p < 0.05, **p < 0.01
bMean max score, indicating collagen-induced arthritis severity, is the mean (± SEM) of the maximum score for all affected mice in the group
cArea under curve (AUC) is the mean (± SEM) of the sum of scores for mice of the corresponding genotype (days 22–63 for Eae39r and days 30–72 for Eae39r2)
dMice having a score above 10 were euthanized during the experiment as per recommendations of animal welfare authorities
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Genetic variations in regulatory regions of the Tbx3 and
Tbx5 genes
Sequencing of the Tbx3 and Tbx5 genes revealed a num-
ber of variations in regulatory and intronic regions, but
none in the coding region (Table 4). Computational ana-
lysis of these variations predicted that some of these
might affect promoter function, transcription factor
binding, or microRNA (miRNA) binding (Table 4).
Reduced expression of Tbx3 in B lymphocytes
Since variations in the regulatory regions of the genes
may affect DNA transcription, mRNA levels of Tbx3 and
Table 2 Anti-collagen type II antibody levels in serum of Eae39r2 sub-congenic mice
Congenic
fragment
Days after collagen
type II immunization
Antibody
isotype
Antibody titers in groups of mice (AU/ml)a Statisticsb
Homozygous Congenic Littermate controls p value
Eae39r2 15 (preclinical phase) IgG1 252 ± 46 96 ± 26 0.0041**
IgG2C 148 ± 11 77 ± 10 < 0.0001****
IgG3 7 ± 0.5 4 ± 0.3 0.0067**
IgM 55 ± 3 37 ± 4 0.0002***
72 (clinical phase) IgG1 5044 ± 1363 1852 ± 486 0.0002***
IgG2C 822 ± 113 323 ± 45 < 0.0001****
IgG3 9 ± 0.5 5 ± 0.4 < 0.0001****
IgM 11 ± 4 9 ± 3 0.144
aArbitrary units per ml (AU/ml) are calculated in comparison to a standard curve of pooled serum from arthritic mice in the same experiment
bData were analyzed using the Mann-Whitney U test; *p < 0.05, **p < 0.01, ***p < 0.001
Table 3 Genetic elements located in the Eae39r2 region, their expression, and literature overview
Genetic Elementa Expressionb Literature summary
Tbx3 (+) Expressed in colon, lung, heart, liver, adrenal
gland and spleen
Controls cell proliferation and differentiation [37, 60, 62];
enhances tumor invasiveness [18]; regulates gene splicing [68];
modulates number of cell signaling pathways involved in the
development of limb, mammary gland, and heart [18]; regulates
bone formation [69, 70] and bone resorption [71]; downregulated
in the early phase of collagen-induced arthritis (CIA) [21]; linked to
rheumatoid arthritis (RA) in a genome-wide association study
(GWAS) [72]; and modulated in RA twin lymphoblastoid B cell lines
compared with healthy co-twin LCLs [73].
Tbx5 (+) Expressed in heart, lung, bone, and urinary
bladder
Controls cell proliferation, differentiation and migration [74, 75];
involved in cell signaling pathways [76–78]; regulates bone growth
and maturation [20, 79] and system development [80, 81];
downregulated in the early phase of CIA [21]; linked to
osteochondrosis in GWAS [82] and RA by activation of RA
synovial fibroblasts [83].
Rbm19 (+) Expressed in heart, lung, uterus, and skeletal
muscle
Key role in synthesis of the small eukaryotic ribosome
subunit [84], pre-implantation development [13], and
mammary gland morphology [85].
1700081H04Rik (+) Expressed in testis, brain, heart, kidney and liver No data available
n-R5s175 (+) Expressed in kidney, liver, testis, brain, spleen,
skeletal tissue, and lung
No data available
Tbx3os1 (−) Expressed in liver, lung, colon, brain, kidney,
skeletal muscle, spleen, and testis
No data available
Gm16063 (+) Expressed in liver, lung, colon, brain, kidney,
skeletal muscle, spleen, and testis
No data available
Gm16064 (+) Expressed in colon, kidney, lung, spleen, brain,
liver, skeletal muscle, and testis
No data available
Tbx3os2 (−) Expressed in kidney, lung, brain, colon, liver,
adrenal gland, and spleen
No data available
Gm10390 (−) Expressed in brain, liver, spleen, testis, heart,
skeletal muscle, colon, and lung
No data available
aBased on Ensembl release 74; protein coding genes are shown in bold; (+) indicates genetic element annotated on forward strand and (−) indicates
reverse strand
bExpression documented for C57BL6 mouse strain in atlas by European Bioinformatics Institute [28]; organs of high expression are shown in bold
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Table 4 Genetic variations between B10.RIII and Eae39r2 sub-congenic mice
Genetic variations related to the mouse Tbx3 gene
SNP ID Location in genomea Allelesb Functional class Predicted consequencec
rs234834055 5:119669859 C/− Promoter variant May affect gene expression level
rs48522093 5:119670996 C/G 5’ UTR variant Introduction of new TFBS for f (alpha)-f (epsilon)
(undocumented role)
rs221652067 5:119674641 −/AATT Intronic variant No TF binding site in this region
rs48057748 5:119675826 G/T Intronic variant No TF binding site in this region
rs260549092 5:119677177 −/A Intronic variant No TF binding site in this region
rs260388829 5:119680214 C/T Intronic variant Disruption of TFBS for c-Rel (member of NF-ĸB TF family,
linked to CIA development, and lymphoid cell growth and
development [86]) and Sp1 (involved in cellular processes
including growth, differentiation and apoptosis)
rs223041783 5:119681737 −/(GA)6 Intronic variant No TF binding site in this region
No SNP id 5:119684553 A/− 3’ UTR variant Lies very close to mmu-miR-511 binding site (miR-511negatively
regulates growth and metastasis of tumor cells in humans [87])
rs254153782 5:119684580 A/C 3’ UTR variant No miRNA binding site in this region
Genetic variations related to the mouse Tbx5 gene
SNP ID Location in genomea Allelesb Functional class Predicted consequencec
rs247725267 5:119834384–
119,834,391
(TTCC)2/
−
Promoter variant May affect expression level of gene
rs46426184 5:119859957 A/G Intron variant No TF binding site in this region
rs222502452 5:119860635 C/T Intron variant No TF binding site in this region
rs32145767 5:119860705 G/A Intron variant No TF binding site in this region
rs242983646 5:119860887 A/C Intron variant Disruption of c-fos binding site (involved in cell proliferation,
growth and survival pathways, including bone and immune
cells [88])
rs252594029 5:119861058 T/C Intron variant No TF binding site in this region
rs246838998 5:119862700 A/G Intron variant No TF binding site in this region
rs213393759 5:119862716 G/A Intron variant No TF binding site in this region
rs32145773 5:119863349 T/C Intron variant Disruption of Sox5 binding site (linked to Th17 cell
differentiation [89])
rs32146450 5:119867116 C/T Intron variant No TF binding site in this region
rs50869445 5:119868930 T/C Intron variant No TF binding site in this region
rs48190630 5:119868943 T/C Intron variant Introduction of new TFBS for C/EBPbeta (regulating the
expression of genes involved in immune and
inflammatory responses [90])
rs32147927 5:119868969 C/T Intron variant No TF binding site in this region
rs228127170 5:119868977 G/A Intron variant No TF binding site in this region
rs49608882 5:119869004 C/T Intron variant No TF binding site in this region
rs45644322 5:119869140 G/A Intron variant No TF binding site in this region
rs48943542 5:119869144 G/A Intron variant No TF binding site in this region
rs6373056 5:119871760 G/A Intron variant No TF binding site in this region
rs48054187 5:119878634 C/T Intron variant No TF binding site in this region
rs265584798 5:119883860 C/T 3’ UTR variant No miRNA binding site in this region
rs255866543 5:119884274 A/G 3’ UTR variant Lies very close to mmu-miR-6918-5p binding site
(undocumented role)
rs232783988 5:119885135 −/G 3’ UTR variant No miRNA binding site in this region
rs237950985 5: 119885225 C/T Downstream
variant
NA
rs237459586 5:119885320–
119,885,324
TCTTT/− Downstream
variant
NA
rs258422458 5:119885423 C/T Downstream
variant
NA
aBased on Ensembl release 74 (mouse genome assembly GRCm38)
bAlleles are mentioned as B10.RIII/Eae39r2
cInformation is based on transcription factor binding site (TFBS) prediction by ConSite [32] and PROMO [33] tools, and miRNA target prediction by miRDB [34]
CIA collagen-induced arthritis
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Tbx5 were measured in the spleens and joints of naïve
B10.RIIIS/J-Eae39r2 sub-congenic and littermate control
mice. Both Tbx3 and Tbx5 were equally expressed in the
joints of naïve sub-congenic and control mice (Fig. 3a,
b). On the contrary, the sub-congenic mice had signifi-
cantly less Tbx3 mRNA in the spleen as compared to
the control mice (p = 0.0036, Fig. 3c), while Tbx5 was
not detectable in the spleen.
In order to determine which cell type mainly contributed
to the expression of Tbx3 in the spleen, quantitative
RT-PCR was carried out on purified B and pan T
lymphocytes. We found that Tbx3 expression was only de-
tectable in B lymphocytes, and B10.RIIIS/J-Eae39r2
sub-congenic mice had significantly less Tbx3 transcripts in
B lymphocytes as compared to the control mice (p =
0.0286, Fig. 3d).
TBX3 is associated with B cell proliferation but not
development of B cells
To investigate whether the observed differential expres-
sion of Tbx3 in the Eae39r2 sub-congenic mouse spleen
was accompanied by altered immune cell activation, an
Fig. 3 Effect of the Eae39r2 sub-congenic fragment on Tbx5 (a) and Tbx3 (b) mRNA levels in the joints, Tbx3 mRNA levels in spleen (c) and
purified splenic B lymphocytes (d). Values are presented as mean of 2^-ΔΔCt and bars represent standard error of the mean (SEM). Statistical
analyses were performed using two-way Student’s t test; *p < 0.05, **p < 0.01
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in vitro proliferation assay was performed with purified
CD19+ B cells from naïve B10.RIIIS/J-Eae39r2 sub-con-
genic and control mice. B cell proliferation was signifi-
cantly increased in the sub-congenic mice in response
to anti-IgM stimulation (p = 0.0317, Fig. 4a). However,
no difference in proliferation of B cells upon stimula-
tion with either LPS or anti-CD40 antibody/IL-4 was
observed (Fig. 4b-c). Furthermore, no difference in pro-
liferation or IL-2 production by purified CD4+ T cells,
following stimulation with anti-CD3/CD28 antibodies,
was observed when comparing sub-congenic mice with
littermate controls (Fig. 4d-e).
To determine whether the reduced expression of
Tbx3 had an effect at the B cell developmental level,
the total and relative numbers of splenic B cells in naïve
B10.RIIIS/J-Eae39r2 sub-congenic and control mice
were determined by automated cell counter and flow
cytometry, respectively. No difference in the absolute
number of splenic B cells (mean ± SEM, B10.RIIIS/
J-Eae39r2 sub-congenic 38.4 × 106 ± 2.8 × 106 (n = 5),
control 36.9 × 106 ± 3.0 × 106 (n = 7)) and relative num-
ber of splenic B cells (mean ± SEM: B10.RIIIS/J-Eae39r2
sub-congenic 59.9% ± 0.8 (n = 10), control 58.7% ± 0.5
(n = 7)) was found between the two groups of mice, in-
dicating that TBX3 is associated with proliferation of B
cells, but not the number.
We further analyzed changes in intra-nuclear TBX3
levels in relation to B cell activation and proliferation
by comparing the quantity of active TBX3 in unstimu-
lated B cells and in B cells activated through the BCR
by anti-IgM antibody. We found that TBX3 activity in B
cells was strongly downregulated upon in vitro stimulation
with anti-IgM antibody (p = 0.0286; Fig. 5a). These data
suggested that TBX3 is involved in BCR downstream
pathways and might contribute to humoral immune
responses.
TBX3 activity varies in splenic B cells during the course of
CIA
Based on our findings, we sought to examine the activity
of TBX3 in B cells during the course of CIA. In that
time-course study, mice started to show signs of arthritis
on day 37 post immunization, which peaked around day
50 and slightly declined in the late phase, as shown in
Fig. 5b. The overall incidence of disease was 75%, which
is in accordance with previous reports on the B10.RIII
mouse strain [42]. By comparing the intra-nuclear TBX3
activity in purified B cells, we found that the amount of
active TBX3 falls significantly in the early pre-clinical
phase (days 7 and 15) and early clinical phase (day 42)
after receiving the first and booster dose of collagen, re-
spectively (Fig. 5c). Furthermore, a significant decrease
in the level of TBX3 was observed upon ex vivo re-
stimulation of the B cells with anti-IgM antibody, at all
timepoints of sampling in CIA (Fig. 5c). On the con-
trary, no significant variation in TBX3 activity was
found in joint tissue homogenates from the same CIA
time-points as for splenic B cells (data not shown).
TBX3 - a potential biomarker of arthritis
By studying the kinetics of TBX3 protein expression
in serum, we made two key observations: first, TBX3
can be measured in mouse serum and second, it is
dynamic along the timeline of CIA, with a consider-
able rise in the clinical phases (days 42 and 68) of
disease in comparison to naïve and pre-clinical levels
(Fig. 6a). Moreover, we showed that arthritic mice
(sick mice from days 42 and 68 samples; n = 6) had
significantly higher TBX3 levels in serum than immu-
nized, non-arthritic mice (days 7, 15, 25, and
non-arthritic mice from days 42 and 68; n = 14) (p =
0.0087) and naïve control mice (p = 0.0095) Fig. 6b.
Spearman’s correlation coefficient was calculated to
determine the relationship between the CIA clinical
score and TBX3 serum levels (rs = 0,62, n = 24, p =
0,0012). These data suggest that severity of arthritis
in the CIA model is associated with an increased
serum concentration of TBX3.
Discussion
In this study, we have shown that a 1.4-Mbp locus lo-
cated on mouse chromosome 5, comprising three pro-
tein coding genes and a number of non-protein coding
genetic elements (Fig. 1), controls the severity of clin-
ical arthritis in CIA along with anti-CII antibody titers.
Based on a literature survey and the link to other bone
diseases in humans, we selected Tbx3 and Tbx5, as po-
tential candidate genes for CIA. We demonstrated vari-
ations in the regulatory part of the Tbx3 gene, which
may affect the observed difference in expression level
of Tbx3 in splenic B lymphocytes, in addition to the in-
creased in vitro B cell activation and proliferation upon
stimulation through cell-bound IgM. Moreover, our
functional data showed that TBX3 activity is inversely
related to B cell activation both in vitro and in the CIA
model. This suggests that TBX3 is a player in CIA
pathogenesis by modulating B cell proliferative re-
sponses, but that it does not affect the development of
B lymphocytes.
Identification of quantitative trait loci (QTLs), genetic
fine-mapping by using congenic and sub-congenic mice,
and the discovery of novel candidate genes, have led to
the identification of molecular interactions that underlie
complex diseases [43–45]. In this study, we fine-mapped
a previously reported QTL, Eae39, linked to CIA [8, 10].
By breeding of sub-congenic lines and by using the same
immunization protocol, we have shown that the Eae39
region contains a smaller QTL (Eae39r), which
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encompasses 1.8 Mbp and has an enhancing effect on
CIA severity. The genes within the fragment are Med13l,
Tbx3, Tbx5, and Rbm19, coding for the mediator complex
subunit 13-like protein, the T-box protein 3, T-box protein
5, and RNA binding motif protein 19, respectively. CIA
experiments with sub-congenic mice provide an attractive
opportunity to study the individual (or combined) contri-
bution of these genes towards arthritis development. We
have previously shown that B10.RIIIS/J-Eae39r1 sub-
congenic mice (with only Med13l in the sub-congenic
fragment) develop arthritis to the same extent as the
wild-type B10.RIII mice [46]. In the current study, we
showed that B10.RIIIS/J-Eae39r2 sub-congenic mice
(with Tbx3, Tbx5 and Rbm19 in the sub-congenic frag-
ment) develop more severe arthritis compared to the
control mice. Taken together, it is reasonable to conclude
that the CIA-enhancing effect seen in the B10.RIIIS/
J-Eae39r mice is due to the genes located in the Eae39r2
Fig. 4 In vitro proliferative response of CD19+ B cells and CD4+ T cells from B10.RIIIS/J-Eae39r2 sub-congenic mice. 3H-thymidine incorporation,
represented as cpm ± SEM, of CD19+ B cells following in vitro stimulation with titrated concentrations (0–40 μg/ml) of anti-IgM antibody (a);
titrated concentrations (0–10 μg/ml) of lipopolysaccharide LPS (b); combination of fixed concentration (10 ng/ml) of IL-4 and titrated concentrations
(0–4 μg/ml) of anti-CD40 antibody (c). d 3H-thymidine incorporation of CD4+ T cells following in vitro stimulation with combination of titrated
concentrations (0–3 μg/ml) of anti-CD3 antibody and fixed concentration of anti-CD28 antibody (3 μg/ml). e IL-2 production (mean ± SEM) in the
supernatant of CD4+ T cells stimulated with anti-CD3/CD28 antibodies. Statistical analyses were performed using the Mann-Whitney U test; *p < 0.05
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Fig. 5 Quantitative analysis of active TBX3 in nuclear lysates of CD19+ B cells from B10.RIII mice. a Comparison of active TBX3 levels in CD19+ B
cells isolated from naïve B10.RIII mice (n = 4), with and without in vitro stimulation with a fixed concentration (10 μg/ml) of anti-IgM antibody for
48 h. b, c Collagen-induced arthritis (CIA) development and corresponding TBX3 activity in B10.RIII mice whereby four mice were killed at indicated time
points after collagen type II (CII) immunization and levels of active TBX3 were determined with and without ex vivo re-stimulation with fixed concentration
(10 μg/ml) of anti-IgM antibody for 48 h. Statistical analyses were performed using the Mann-Whitney U test; *significant (p< 0.05) compared to day 0
unstimulated samples; #significant compared to day 7 unstimulated samples; §significant compared to respective unstimulated samples
Fig. 6 Kinetics of the expression of the TBX3 protein during development of collagen-induced arthritis (CIA) in the B10.RIII mouse strain. Levels of
TBX3 in serum from CIA-immunized mice (a); comparison of serum-TBX3 levels between naïve mice (n = 4), immunized, non-arthritic mice (n = 14)
and arthritic mice (n = 6) (b). Statistical analyses were performed using the Mann-Whitney U test; **p < 0.01
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fragment and that MED13L has minimal or no effect on
CIA development. Additionally, the Eae39r2 region con-
trols the anti-CII antibody response.
Within the Eae39r2 locus, two evolutionarily related
genes, Tbx3 and Tbx5, were chosen as potential candi-
date genes controlling CIA severity based on the con-
sensus criterion recommended by the Complex Trait
Consortium [47]. We cannot, however, disregard the in-
volvement of non-coding genes within Eae39r2. In this
study we have reported a number of polymorphisms in
regulatory regions of the Tbx3 and Tbx5 genes when
comparing the B10.RIII and RIIIS/J parental mouse
strains. Some of the polymorphisms are predicted to
affect the transcription and protein expression levels by
modulating promoter activity, transcription factor bind-
ing, or microRNA binding. We propose that one or
more of these variants are responsible for the allele-spe-
cific differences in Tbx3 transcript levels observed in
total spleen and splenic B lymphocytes, but not in joints.
This can be explained by tissue-specific regulation of
Tbx3 that has been previously documented in mice [18]
and humans [18, 25].
It has recently been acknowledged that B lymphocytes
and autoantibodies are key in aspects of RA pathogen-
esis [48, 49] and the clinical success of B cell targeted
therapies further strengthens this [6, 50]. Although not
directly demonstrated, we believe that decreased ex-
pression of Tbx3 in B lymphocytes from mice with a
1.4-Mbp fragment derived from a genetically different
mouse strain, in addition to the increased in vitro pro-
liferation of these cells in response to anti-IgM stimula-
tion, is a finding that can explain the enhanced antibody
response and more severe disease in these mice. We sug-
gest that the increased proliferation of B cells from the
B10.RIIIS/J-Eae39r2 sub-congenic mice in response to
anti-IgM stimulation, but not to LPS or anti-CD40/IL-4
treatment, might be the result of TBX3 interacting with
specific components of the intracellular pathways acti-
vated. Anti-IgM antibodies stimulate B cells through the B
cell receptor (BCR) thereby activating further downstream
signaling cascades like the phosphatidylinositol 3-kinase
(PI3K), protein kinase B (AKT) and mitogen-activated
protein kinase (MAPK) pathways [51–53]. TBX3 has pre-
viously been shown to directly interact with these signal-
ing cascades in other cell types to regulate cell survival
and proliferation [54–57] and a similar mechanism might
operate in B cells.
The importance of TBX3 in relation to proliferation is
underpinned by studies of its role in oncogenesis [24,
25, 58, 59]. TBX3 functions primarily as a transcriptional
repressor and initial reports suggested that it can pro-
mote proliferation by repressing the cell cycle regulators
p14/p19ARF and p21 [60–62]. More recently, it was rec-
ognized that although TBX3 promotes migration and
invasiveness of cancer cells, it negatively regulates cell
proliferation [37, 63]. In line with these reports of an
anti-proliferative role for TBX3, our study suggests that
it might be controlling cell cycle regulators in B lympho-
cytes under normal conditions. Lack of, or low expres-
sion of Tbx3, may thus lead to increased activation of B
lymphocytes, manifested by proliferation and increased
autoantibody production, which subsequently would
cause severe arthritis in the CIA model. To this end, we
demonstrated that the level of functionally active TBX3
in B cells falls after in vitro activation through the BCR.
Furthermore, our in vivo results from the time-course
CIA study show that TBX3 activity falls significantly
when the immune system is challenged through heterol-
ogous CII immunization. The lowest TBX3 activity was
observed a week after the first injection of immunogen,
which corresponds to the time point reported for the
highest B cell activation and proliferation of CII-specific
IgM-positive B cells in the CIA model [64]. This, again,
suggests that TBX3 interacts with signaling pathways
downstream of the IgM-BCR, thereby being modulated
by, or modulating, the activation signal, resulting in con-
sequences for the outcome of the B cell response.
To our knowledge, this is the first study to suggest
the involvement of TBX3 in B cell proliferation and de-
velopment of CIA, and adds mechanistic links to three
independent genome-wide association studies (GWAS)
that linked TBX3 to RA [65–67]. Whether the TBX3
genetic variant(s) linked to RA in these studies repre-
sents a true susceptibility variant(s) is still to be investi-
gated. Furthermore, our preliminary data show that
TBX3 is a putative RA biomarker and that an increase
in TBX3 serum levels in untreated arthritis reflects dys-
regulation of currently unidentified disease pathways.
Although the current biomarker study has limitations
in terms of group size and that the studies are per-
formed in an experimental model, the conservation of
this protein and disease pathways between man and
mouse might overcome the discovery step, which is
often a bottleneck in the biomarker field. Future studies
in human cohorts are needed to prove the biomarker
potential of the multifaceted protein, TBX3.
Conclusion
We have fine-mapped the CIA enhancing Eae39r locus
and suggest that the therein located Tbx3 gene is a dis-
ease candidate gene for experimental arthritis in the
mouse. From studies of gene transcription and B cell
proliferation, we propose that TBX3 impacts CIA devel-
opment and autoantibody production by regulating B
lymphocyte activation. Taken together, these results indi-
cate that TBX3 is involved in RA pathogenesis and pos-
sibly also in other autoimmune diseases dependent on B
cell activation and autoantibody production. By
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investigating intracellular TBX3 protein activity in B
cells upon stimulation through the B cell receptor, we
have shown that activation of B cells is concomitant with
low levels of active TBX3 in vitro. Moreover, we ob-
served that serum levels of TBX3 follow arthritis sever-
ity. We therefore propose TBX3 as a candidate
biomarker that can potentially aid in diagnosis and as-
sessment of RA disease severity.
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